Browsing by Author Tonkin, Andrew M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)Citation
2002Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and establisheed ischaemic heart disease: is it cost effective?Eckermann, Simon; Kirby, Adrienne; Martin, Andrew; Mulray, Sarah; Simes, Robert John; Caleo, Susan; Glasziou, Paul P; Hall, Jane P; Tonkin, Andrew M; White, Harvey D; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and establisheed ischaemic heart disease: is it cost effective?, Medical Journal of Australia, vol.177,(8),2002,pp 428-434
2015Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian ReviewChow, Clara Kayei; Keech, Anthony (Tony); Barter, Philip; Grenfell, Robert; Nicholls, Stephen; Sullivan, D; Tonkin, Andrew M; Watts, Gerald F; Western Clinical School: Medicine (Westmead); NH&MRC Clinical Trials CentreClinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review, Heart, Lung and Circulation, vol.24, 5, 2015,pp 495-502
2002Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factorsKeech, Anthony (Tony); Braunwald, Eugene; Craven, Timothy; Furberg, Curt D; Pfeffer, Marc A; Sacks, Frank M; Shepherd, James; Tonkin, Andrew M; School of Public Health: NH&MRC Clinical Trials CentreCoronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors, Circulation (Baltimore), vol.105,(12),2002,pp 1424-1428
2003Depression and cardiovascular morbidity and mortality: cause or consequence?Simes, Robert John; Colquhoun, David; North, Fiona M.; Sharples, Katrina J.; Stewart, Ralph A.H.; Tonkin, Andrew M; West, Teena M.; White, Harvey D; School of Public Health: NH&MRC Clinical Trials CentreDepression and cardiovascular morbidity and mortality: cause or consequence?, European Heart Journal, vol.24,(N/A),2003,pp 2027-2037
2016Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular diseaseNeal, Bruce; Patel, Anushka; Rodgers, Anthony; Stepien, Sandrine; Usherwood, Timothy; Webster, Ruth; Arroll, Bruce; Bots, Michiel L.; Bramley, Dale M.; Bullen, Chris; Cass, Alan; Grobbee, Diederick E.; Hillis, Graham; Molanus, Barbara; Rafter, Natasha; Selak, Vanessa; Thom, Simon; Tonkin, Andrew M; Wadham, Angela; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Western Clinical School: General Practice; The George Institute for Global HealthDo polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease, European Journal of Preventive Cardiology, vol.23, 13, 2016,pp 1393-1400
2014An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trialHayes, Alison; Jan, Stephen; Lo, Serigne; Neal, Bruce; Patel, Anushka; Peiris, David; Rodgers, Anthony; Usherwood, Timothy; Cass, Alan; Hillis, Graham; Laba, Tracey-Lea; Rafter, Natasha; Reid, Christopher; Tonkin, Andrew M; Webster, Ruth; School of Public Health: Public Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Western Clinical School: General PracticeAn economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial, Medical Journal of Australia, vol.201, 11, 2014,pp 671-673
2002Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levelsKeech, Anthony (Tony); Simes, Robert John; Braunwald, Eugene; Davis, B R; Ford, I; Furberg, Curt D; Shepherd, James; Tonkin, Andrew M; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEffects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels, European Heart Journal, vol.23,(3),2002,pp 207-215
2017Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular diseaseAngell, Blake; Billot, Laurent; Jan, Stephen; Laba, Tracey-Lea; Lung, Thomas; Patel, Anushka; Usherwood, Timothy; Brown, Alex; Cass, Alan; Eades, Sandra J; Hillis, Graham; Molanus, Barbara; Peiris, David; Rafter, Natasha; Reid, C; Tonkin, Andrew M; Webster, Ruth; Poche Centre Indigenous Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; Western Clinical School: General PracticeHealthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease, International Journal for Equity in Health, vol.16, 1, 2017,pp 1-7
2016Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID StudyHague, Wendy; Keech, Anthony (Tony); Kirby, Adrienne; Pater, Helen; Simes, Robert John; Sullivan, David; Colquhoun, David; Glasziou, Paul P; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Thompson, Peter; Tonkin, Andrew M; West, Malcolm; White, H D; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study, Circulation, vol.133, 19, 2016,pp 1851-1860
2016Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID StudyHague, Wendy; Keech, Anthony (Tony); Kirby, Adrienne; Pater, Helen; Simes, Robert John; Sullivan, David; Colquhoun, David; Glasziou, Paul P; Hunt, David; Nestel, Paul; Stewart, Ralph A.H.; Thompson, Peter; Tonkin, Andrew M; West, Malcolm; White, H D; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study, Circulation, vol.133, 19, 2016,pp 1851-1860
2014Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID studyMann, Kristy; Simes, Robert John; Sullivan, David; Blankenberg, Stefan; Colquhoun, David; Funke-Kaiser, Anne; Hunt, David; Sydow, Karsten; Tonkin, Andrew M; West, Malcolm; White, Harvey; Zeller, Tanja; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreMidregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study, International Journal of Cardiology, vol.172, 2, 2014,pp 411-418
2015The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility StudyPerkovic, Vlado; Badve, Sunil V.; Cass, Alan; Garg, Amit X.; Hawley, Carmel; Ierino, Francesco L.; Isbel, Nicole; Krum, Henry; Pascoe, Elaine; Pilmore, Helen; Roberts, Matthew A; Tonkin, Andrew M; Vergara, Liza A; The George Institute for Global HealthThe rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study, Nephrology, vol.20, 3, 2015,pp 140-147
2002Risk factors for non-haemorraghic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatinKirby, Adrienne; Simes, Robert John; Simes, Susan; Watson, John; Anderson, Neil E; Hankey, Graeme J; Hunt, David; Tonkin, Andrew M; West, Malcolm J; White, Harvey D; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineRisk factors for non-haemorraghic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin, Journal of Hypertension, vol.20,(12),2002,pp 2513-2517
2002Safety and tolerability of pravastatin in long-term clinical trialsKeech, Anthony (Tony); Braunwald, Eugene; Byington, Robert P; Cobbe, Stuart M; Davis, B R; Friedman, Carola P; Pfeffer, Marc A; Sacks, Frank M; Tonkin, Andrew M; School of Public Health: NH&MRC Clinical Trials CentreSafety and tolerability of pravastatin in long-term clinical trials, Circulation (Baltimore), vol.105,(20),2002,pp 2341-2346
2008The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID studyKirby, Adrienne; Pollicino, Christine; Simes, Robert John; Sullivan, David; Bickel, Christoph; Blankenberg, Stefan; Lubos, Edith; Munzel, Thomas F; Nestel, P; Schnabel, Renate; Tiret, Laurence; Tonkin, Andrew M; West, Malcolm J; White, Harvey D.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; Molecular & Microbial BioscienThe value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study, European Heart Journal, vol.29,(8),2008,pp 923-931